Zevra Therapeutics
ZVRA
34 hedge funds and large institutions have $43.5M invested in Zevra Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 6 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
101% more capital invested
Capital invested by funds: $21.7M → $43.5M (+$21.8M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
10% more funds holding
Funds holding: 31 → 34 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
+$843K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$745K |
| 3 |
JP Morgan Chase
New York
|
+$604K |
| 4 |
Renaissance Technologies
New York
|
+$546K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$1.55M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$603K |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$289K |
| 4 |
MC
Menta Capital
San Francisco,
California
|
-$109K |
| 5 |
BlackRock
New York
|
-$76.4K |
ZVRA Hedge Fund Activity: Q1 2018 in Review
34 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2018, worth a combined $43.5M — up 101% from $21.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ZVRA positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was ING Group, opening a new position worth an estimated $843K. The largest seller was Arete Wealth Advisors, cutting an estimated $1.55M.
- 34 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2018, up from 31 in Q4 2017.
- Funds reported $43.5M of Zevra Therapeutics stock for Q1 2018, up 101% quarter-over-quarter.
- 9 funds opened new Zevra Therapeutics positions in Q1 2018 and 6 closed out, a net change of +3 holders.
- The largest Zevra Therapeutics buyer in Q1 2018 was ING Group, an estimated $843K added.
- The largest Zevra Therapeutics seller in Q1 2018 was Arete Wealth Advisors, an estimated $1.55M sold.
Based on aggregated 13F filings for Q1 2018.